You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

NAION risk is most significant within the first 12 months of beginning semaglutide, and is highest in patients with additional risk factors.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...